PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Lignende værker

• Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
  af: Ricardo D. Parrondo, et al.
  Udgivet: (2024-09-01)
• PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  af: Katja Weisel, et al.
  Udgivet: (2023-08-01)
• Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
  af: Andrew J. Yee, et al.
  Udgivet: (2025-03-01)
• P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
  af: I. Vaxman, et al.
  Udgivet: (2022-06-01)
• The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
  af: Hitomi Nakayama, et al.
  Udgivet: (2024-09-01)